Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 310-330 , June 2005

Introduction of direct-to-consumer advertising of prescription drugs in Canada: An opinion survey on regulatory policy

  • Barbara Mintzes, Ph.D.

      Affiliations

    • Centre for Health Services and Policy Research, University of British Columbia (UBC), Vancouver, BC Canada V6T 1Z3
    • Corresponding Author InformationCorresponding author.
    • ,
  • Morris Barer, M.B.A., Ph.D.

      Affiliations

    • Centre for Health Services and Policy Research, University of British Columbia (UBC), Vancouver, BC Canada V6T 1Z3
    • Department of Health Care and Epidemiology, University of British Columbia, Vancouver, BC Canada V6T 1Z3
    • ,
  • Joel Lexchin, M.D.

      Affiliations

    • School of Health Policy & Management, Atkinson Faculty of Liberal and Professional Studies, York University, Toronto, Ontario, Canada M3J 1P3
    • ,
  • Ken L. Bassett, M.D., Ph.D.

      Affiliations

    • Departments of Family Practice and Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC Canada V6T 1Z3

References 

  1. Masson A. Direct-to-consumer advertising: a continuing controversy. In: Proceedings of the Second International Conference on Research in the Consumer Interest. Snowbird, Utah, USA, August 1990. Columbia, Mo: American Council on Consumer Interests; 1991;p. 159–168
  2. IMS Health . Total US promotional spending by type, 2003. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_44304752_44889690,00.htmlMarch 5, 2004;Accessed March 2005
  3. Findlay S. Prescription Drugs and Mass Media Advertising. Available from: Washington, DC: National Institute of Health Care Management; September 2000;www.nihcm.orgAccessed December 2002
  4. Topol EJ. Failing the public health—Rofecoxib, Merck and the FDA. N Engl J Med. 2004;351:1707–1709
  5. Anonymous . Merck & co invents new syndrome—information deprivation. Scrip. 2004;2983:5
  6. Meek C. Direct-to-consumer advertising (DTCA) of Prescription Medicines: Fourth Quarterly Update—October to December 2002. Available from: London: Royal Pharmaceutical Society of Great Britain; January 3, 2003;http://www.rpsgb.org/pdfs/dtcarev0212.pdfAccessed March 2005
  7. Galbally R. Review of drugs, poisons, and controlled substances legislation. Draft Final Report. Therapeutic Goods Administration, Canberra, Australia http://www.health.gov.au/tga/docs/html/rdpdfr.htmSeptember 2000;Accessed January 2002
  8. Berndt ER. To inform or persuade? Direct-to-consumer advertising of prescription drugs. N Engl J Med. 2005;352:325–326
  9. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA. 1999;281:381–382
  10. Bell RA, Wilkes MS, Kravitz RL. The educational value of consumer-targeted prescription drug print advertising. J Fam Pract. 2000;49:1092–1098
  11. Woloshin S, Schwartz LM, Tremmel J, Welch HG. Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?. Lancet. 2001;358:1141–1146
  12. US FDA. Direct-to-you: DTC ads that make sense. [Consumer Talk Paper] Rockville, Md. December 3, 2001. <http://www.fda.gov/cder/about/whatwedo/testtube-11.pdf>. Accessed 03.09.05.
  13. FDA proposes new guidance on direct-to-consumer ads. Scrip. August 15, 1997;2258:12
  14. Quick JD, Hogerzheil HV, Rago L, Reggi V, de Joncheere K. Ensuring ethical drug promotion—whose responsibility?. Lancet. 2003;362:747
  15. Dyer C. Incontinence campaign tests limits of advertising rules. BMJ. 1999;319:591–592
  16. Mintzes B. Direct to consumer advertising is medicalising normal human experience. BMJ. 2002;324:908–911
  17. Noonan D. GM's war on drug costs. Newsweek. 2001;February 26:46
  18. Canadian Institute for Health Information . Drug expenditure in Canada 1985 to 2003. Ottawa <www.cihi.ca>2004;Accessed February 2005
  19. Health Products and Food Branch, Health Canada. Direct-to-consumer advertising of prescription drugs. [discussion document]. April 6, 1999. <www.hc-sc.gc.ca/hpfb-dgpsa/oria-bari/99-04-14_3_e.html>. Accessed March 2005.
  20. Mintzes B, Barer ML, Kazanjian A, Bassett K, Evans RG, Morgan S. An assessment of the health system impact of direct-to-consumer advertising of prescription medicines (DTCA). Volume I: Executive Summary. Centre for Health Services and Policy Research. <http://www.chspr.ubc.ca/hpru/pdf/dtca-v1-execsum.pdf>. Accessed March 2005.
  21. Brown B, chair for Standing Committee on Health . Opening the Medicine Cabinet: First Report on Health Aspects of Prescription Drugs. Ottawa, Canada: House of Commons <http://www.parl.gc.ca>April 2004;
  22. Health Canada. Health Protection Legislation. Detailed Legislative Proposal. Ottawa. 2003. <http://www2.itssti.hc-sc.gc.ca/HPCB/Policy/LegislativeRenewal.nsf/fb7c4e1fc0e11e1c85256d24006a12e5/b89331835ada362b85256d3d004f10f3/$FILE/WEBSITEENGLPROPOSALFINAL.pdf>. Accessed March 2005.
  23. Gardner DM, Mintzes B, Ostry A. Direct-to-consumer prescription drug advertising in Canada: permission by default?. Can Med Assoc J. 2003;169:425–427
  24. Michols D. The distinction between advertising and other activities. Therapeutic products programme. Issued January 12, 1996; updated November 3, 2000. <http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/advsactv_e.pdf>. Accessed March 2005.
  25. Rowsell LB. Policy statement. Advertising campaigns of branded and unbranded messages. Therapeutic Products Directorate, Health Canada. November 2000. <http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/policy/issued/adv_campaign_e.html>. Accessed December 2004.
  26. Brodie M. Understanding the Effects of Direct-to-consumer Prescription Drug Advertising. Menlo Park, Calif: The Henry J. Kaiser Family Foundation; 2001;
  27. Mintzes B, Barer ML, Kravitz RL, et al. How does direct-to-consumer advertising (DTCA) affect prescribing? A survey in primary care environments with and without legal DTCA. Can Med Assoc J. 2003;169:405–412
  28. Wazana A. Physicians and the pharmaceutical industry. Is a gift ever just a gift?. JAMA. 2000;283:373–380
  29. Slaughter E, Schumacher M. Prevention's international survey on wellness and consumer reactions to DTC Advertising of Rx drugs. Prev Mag. 2000/2001;Rodale Press
  30. Scott Levin. Patient visits up for DTC conditions. Newtown, Pa: Press Release; November 6, 1998;<www.scottlevin.com>Accessed September 1999
  31. Weissman JS, Blumenthal D, Silk AJ, Zapert K, Newman M, Leitman R. Consumers' reports on the health effects of direct-to-consumer drug advertising. Health Aff. February 26, 2003;[Web Exclusive]
  32. Innvaer S, Vist G, Trommald M, Oxman A. Health policy-makers' perceptions of their use of evidence: a systematic review. J Health Ser Res Policy. 2002;4:239–244
  33. US General Accounting Office. FDA drug review. Postapproval risks 1976-1985. Report to the Chairman, Subcommittee on Human Resources and Intergovernmental Relations. Committee on Government Operations. Washington DC. April 1990, GAO/PEMD/90-15.
  34. Lasser K, Allen P, Woolhandler S, Himmelstein D, Wolfe S, Bor D. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215–2220
  35. Petersen M. What's black and white and sells medicine?. N Y Times. August 27, 2000;12;[sect 3, p1]
  36. Coney S. Direct-to-consumer advertising of prescription pharmaceuticals: a consumer perspective from New Zealand. J Public Policy Market. 2002;21:213–223
  37. Researched Medicines Industry (RMI). Direct to consumer advertising can enhance public health. The case for direct-to-consumer prescription medicine advertising. Wellington NZ. June 2000.
  38. Brown P. Will DTC advertising shape the future of the industry?. Scrip Mag. 1998;3–4
  39. Bell RA, Kravitz RL, Wilkes MS. Direct-to-consumer prescription drug advertising 1989-1998. A content analysis of conditions, targets, inducements and appeals. J Fam Pract. 2000;49:329–335
  40. World Health Organization . Ethical Criteria for Medicinal Drug Promotion. 1988;Geneva <http://www.who.int/medicines/library/dap/ethical-criteria/criteriamedicinal.pdf>Accessed March 2005
  41. Burton B. New Zealand moves to ban direct advertising of drugs. BMJ. 2004;328:68
  42. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;36:475–481

PII: S1551-7411(05)00039-2

doi: 10.1016/j.sapharm.2005.03.007

Research in Social and Administrative Pharmacy
Volume 1, Issue 2 , Pages 310-330 , June 2005

Article Tools

* Image Usage & Resolution